<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05098821</url>
  </required_header>
  <id_info>
    <org_study_id>PRI-ADD</org_study_id>
    <nct_id>NCT05098821</nct_id>
  </id_info>
  <brief_title>Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation</brief_title>
  <acronym>AD-Sys</acronym>
  <official_title>Pattern Recognition of Immune Cells in Atopic Dermatitis Patients Receiving Dupilumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if&#xD;
      unresponsive to topical treatment. However, not all patients who suffer from atopic&#xD;
      dermatitis respond similarly to this treatment. Pattern recognition of immune cells (PRI) is&#xD;
      an efficient method to screen patients to allow a more personalized therapy.&#xD;
&#xD;
      The main aim of this scientific explorative study is to unravel the changes in peripheral&#xD;
      blood immune cell compositions in patients with atopic eczema undergoing dupilumab treatment.&#xD;
      This allows the identification of phenotypes of treatment responders and non-responders and&#xD;
      possible approaches of treatment modifications for non-responders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A better understanding of the pathology of atopic dermatitis could lead to the development of&#xD;
      new therapeutic strategies for this disease and contribute to better and more targeted&#xD;
      disease management - an advantage for all patients with atopic dermatitis.&#xD;
&#xD;
      The PRI is a new bioinformatic analysis strategy that allows in-depth data analysis from flow&#xD;
      cytometry with multiple variables. This facilitates the identification of meaningful T cell&#xD;
      subpopulations, which are differentially abundant between two groups to predict responders&#xD;
      and non-responders prior to dupilumab treatment.&#xD;
&#xD;
      Peripheral blood will be collected before, 4 weeks, 8 weeks, and 16 weeks after initiating&#xD;
      the systemic treatment with dupilumab to identify recognition patterns/markers on the T&#xD;
      cells. Therefore, a predefined multicolor flow cytometry panel was developed to analyse&#xD;
      lineage, differentiation and activation markers.&#xD;
&#xD;
      Patients will receive a systemic therapy (dupilumab 600 mg loading dose, followed by 300 mg&#xD;
      in two weeks intervals). Follow up visits will be performed every 3 months starting from the&#xD;
      second visit (2nd visit will take place 4 weeks after initiating Dupilumab treatment).&#xD;
&#xD;
      The blood samples that are taken as part of this scientific study are pseudonymized in the&#xD;
      research laboratories and stored for a period of 5 years after the end of this study or the&#xD;
      publication of the results and destroyed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Comparison of T-cell inflammatory markers</measure>
    <time_frame>1 year</time_frame>
    <description>Identification of at least one pattern recognition profile showing a strong association with responder status to dupilumab therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Different T-cell pattern with dupilumab therapy</measure>
    <time_frame>1.5 years</time_frame>
    <description>Time in which the pattern of T-cell modulation after initiation of dupilumab therapy (measured using PRI) shows significant differences from the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assign recognition patterns to clinical symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>Association of recognition patterns with clinical symptoms of atopic dermatitis (measured using Cramer's V &gt; 0.5) with a specific interest in conjunctivitis, pruritus, asthma and herpes infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Connection of molecular profile and phenotype</measure>
    <time_frame>3 months</time_frame>
    <description>Classification and clustering of at least two molecular profiles of peripheral blood immune cells in relation to phenotypes of atopic dermatitis (Cramer's V either with association to IgE levels or early/late onset AD).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Dupilumab treated Patients</arm_group_label>
    <description>Patients with atopic dermatitis with indication for dupilumab treatments will be observed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>not applicable, observational study</intervention_name>
    <description>Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study</description>
    <arm_group_label>Dupilumab treated Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood mononuclear cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients with moderate to severe atopic dermatitis presenting in the clinic of&#xD;
        Dermatology, Charité - Universitätsmedizin Berlin, Germany&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 and above&#xD;
&#xD;
          -  Diagnosis of atopic dermatitis for ≥1 year&#xD;
&#xD;
          -  Inadequate response to treatment with topical medications&#xD;
&#xD;
          -  Confirmed dupilumab treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age below 18&#xD;
&#xD;
          -  Known or suspected allergy or reaction to any component of the dupilumab formulation&#xD;
&#xD;
          -  Known active allergic or irritant contact dermatitis that is likely to interfere with&#xD;
             the assessment of the severity of AD&#xD;
&#xD;
          -  Severe conjunctivitis or blepharitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dpt of Dermatology and Allergology, Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margitta Worm, Prof. Dr. med.</last_name>
      <phone>+49 30 450 518105</phone>
      <email>margitta.worm@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Dölle-Bierke, PhD</last_name>
      <phone>+49 30 450 518367</phone>
      <email>sabine.doelle@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Margitta Worm, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wojciech Francuzik, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Margitta Worm</investigator_full_name>
    <investigator_title>Prof. Dr. med. Margitta Worm</investigator_title>
  </responsible_party>
  <keyword>dupilumab</keyword>
  <keyword>pattern recognition</keyword>
  <keyword>immune cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

